Nature Reviews Drug DiscoveryThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

947 records returned

Frank DouglasEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 840 (2009). doi:10.1038/nrd3047 The President and Chief Executive Officer of the Austen BioInnovation Institute in Akron discusses the institute's multidisciplinary approach to innovation. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: journals

Patent WatchEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 838 (2009). doi:10.1038/nrd3046 Author: Charlotte Harrison Drug metabolite claims are patentableLaws of nature and natural phenomena are not patentable, but new useful processes or compositions are. So, where does a test that includes methods based on the measurement of drug metabolites fit in? Is drug metabolism a natural process? These (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Authors: Charlotte Harrison Tags: News and Analysis Source Type: journals

News in briefEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 835 (2009). doi:10.1038/nrd3045 Mixed results for first delayed-start trial in Parkinson's diseaseA clinical trial that was designed to examine the possibility that rasagiline (Azilect/Agilect; Teva/Lundbeck) has disease-modifying effects in Parkinson's disease has shown varying results.The lowdown: To date, no treatments for Parkinson's disease have been (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: journals

Novel pharmacotherapies for obesity poised to enter marketEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 833 (2009). doi:10.1038/nrd3044 Author: Dan Jones Phase III trial results for three anti-obesity therapies suggest that they meet at least some of the efficacy benchmarks for regulatory approval, although questions remain about the value of the benefits offered. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Authors: Dan Jones Tags: News and Analysis Source Type: journals

First oral therapies for multiple sclerosis anticipatedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 831 (2009). doi:10.1038/nrd3043 Author: Bethan Hughes With five novel oral therapies in late-stage development, there could soon be a wide range of treatment options for relapsing–remitting multiple sclerosis, but better biomarkers are needed to more effectively address the challenge of treating progressive forms of the disease. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Authors: Bethan Hughes Tags: News and Analysis Source Type: journals

Steering for successEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 829 (2009). doi:10.1038/nrd3042 An FDA initiative to enable companies to discuss options for future trial design following completion of early-stage trials could have an important role in addressing the high costs and failure rates of pivotal clinical trials. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Tags: Editorial Source Type: journals

In this issueEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 827 (2009). doi:10.1038/nrd3041 Unmet medical need and commercial potential are considered to be key drivers of novel drug discovery, but identifying disease areas for which scientific understanding is improving substantially could also have a valuable role in guiding the focus of R&D investment. In their Analysis article, Agarwal (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Tags: In This Issue Source Type: journals

Market watch: Sales of biologics to show robust growth through to 2013Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Market watch: Sales of biologics to show robust growth through to 2013 Nature Reviews Drug Discovery 8, 837 (2009). doi:10.1038/nrd3040 Author: Michael Goodman AVOS Life Sciences has analysed the revenue contributions of biologics and small-molecule drugs to the major Rx drug portfolios (MRDP) of the 14 large-cap pharmaceutical companies. MRDP is the collection of branded drugs that are each predicted to achieve at least US$500 million in annual (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Authors: Michael Goodman Tags: News and Analysis Source Type: journals

Trial watch: CGRP receptor antagonist meets Phase III migraine end pointsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Trial watch: CGRP receptor antagonist meets Phase III migraine end points Nature Reviews Drug Discovery 8, 836 (2009). doi:10.1038/nrd3039 Merck has announced that the antagonist of the calcitonin gene-related peptide (CGRP) receptor telcagepant has met the primary end points in two Phase III trials to treat migraine, which is characterized by attacks of intense throbbing head pain that can last from 4 to 72 (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: journals

Deal watch: Nektar in US$1.5 billion licensing deal with AstraZenecaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Deal watch: Nektar in US$1.5 billion licensing deal with AstraZeneca Nature Reviews Drug Discovery 8, 836 (2009). doi:10.1038/nrd3038 Nektar Therapeutics — a company focused on drug development based on advanced polymer conjugate technology — has announced a licensing deal with AstraZeneca for two compounds to combat opioid-induced constipation. Under the deal, Nektar will receive an upfront payment of US$125 million and up to (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: journals

In briefEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 848 (2009). doi:10.1038/nrd3037 Antibacterial drugs (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Tags: Research Highlight Source Type: journals

Mood disorders: Antidepressant action through gene regulationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 847 (2009). doi:10.1038/nrd3036 Author: Charlotte Harrison A recent paper in the Journal of Neuroscience has shown that inhibitors of histone deacetylases (HDACs) — enzymes that affect the acetylation status of histones and regulate the remodelling of chromatin — have antidepressant actions.Although currently used antidepressants rapidly modulate monoaminergic systems in (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Authors: Charlotte Harrison Tags: Research Highlight Source Type: journals

HIV: A new starting point for HIV vaccine designEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 846 (2009). doi:10.1038/nrd3035 Author: Monica Hoyos Flight Identifying broadly neutralizing antibodies (BNAbs) against HIV, which recognize most manifestations of this highly mutable virus, is important in achieving the elusive goal of developing a viable HIV vaccine. However, although the BNAbs that have been identified are effective in primate models of HIV, they (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Authors: Monica Hoyos Flight Tags: Research Highlight Source Type: journals

Cancer: CpG–siRNA deals double blow to tumoursEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cancer: CpG–siRNA deals double blow to tumours Nature Reviews Drug Discovery 8, 847 (2009). doi:10.1038/nrd3034 Author: Alexandra Flemming Tumours can avert an immune response and boost their own growth by inducing the expression of immunosuppressive, angiogenic and growth factors in neighbouring cells. Reporting in Nature Biotechnology, Kortylewski and colleagues now present a new strategy to alter the balance in the tumour microenvironment (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Authors: Alexandra Flemming Tags: Research Highlight Source Type: journals

Antibacterial drugs: Proteasome target to tackle non-replicating TBEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 845 (2009). doi:10.1038/nrd3033 Author: Katie Kingwell The ability of Mycobacterium tuberculosis to enter into a non-replicating state that is not strongly affected by standard antibiotics necessitates long treatment regimens, leading to poor patient compliance that can promote the emergence of drug-resistant strains. Reporting in Nature, Lin and colleagues show (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Authors: Katie Kingwell Tags: Research Highlight Source Type: journals

Metabolic disease: Dual benefit of bile acid receptor agonistEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 848 (2009). doi:10.1038/nrd3032 Author: Sarah Crunkhorn Bile acids, which contribute to the emulsification and digestion of lipid-soluble nutrients following a meal, are increasingly appreciated as also having important roles in metabolic signalling pathways. Writing in Cell Metabolism, Thomas and colleagues identify an agonist of G protein-coupled bile acid receptor 1 (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: journals

NanotechnologyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 911 (2009). doi:10.1038/nrd3029 The translation of nanotechnology-based therapies and products from the laboratory to the clinic requires a multidisciplinary approach. Our two interviewees this month discuss their roles in bringing together diverse groups of scientists to achieve this goal. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Tags: Careers and Recruitment Source Type: journals

AsenapineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
irkpatrick In August 2009, asenapine (Saphris; Schering–Plough) was approved by the US FDA for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Authors: Herbert Y. MeltzerArgyris DritselisUma YasothanPeter Kirkpatrick Tags: News and Analysis Source Type: journals

Influenza vaccine market dynamicsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Rovini The market for seasonal influenza vaccines, sized at US$2.8 billion in 2008–2009 across the seven major markets (United States, Japan, France, Germany, Italy, Spain and UK), has had a strong compound annual growth rate of 12.6% since 2005–2006 (Ref. 1). In recent years, the (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Authors: Hedwig KresseHolger Rovini Tags: News and Analysis Source Type: journals

Targeting protein kinases in central nervous system disordersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
atterson Protein kinases are a growing drug target class in disorders in peripheral tissues, but the development of kinase-targeted therapies for central nervous system (CNS) diseases remains a challenge, largely owing to issues associated specifically with CNS drug discovery. However, several candidate therapeutics that target CNS (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Authors: Laura K. ChicoLinda J. Van EldikD. Martin Watterson Tags: Review Source Type: journals

Can literature analysis identify innovation drivers in drug discovery?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Searls Drug discovery must be guided not only by medical need and commercial potential, but also by the areas in which new science is creating therapeutic opportunities, such as target identification and the understanding of disease mechanisms. To systematically identify such areas of high scientific activity, (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Authors: Pankaj AgarwalDavid B. Searls Tags: Analysis Source Type: journals

A pre-emptive strike against malaria's stealthy hepatic formsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
rges Snounou Almost all the drugs that are widely used today against Plasmodium spp., the causative agent of malaria, target the asexual blood stages of the parasite. Widespread drug resistance severely restricts our ability to control malaria and makes it necessary to seek novel antimalarial compounds. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 30, 2009 Category: Drugs & Pharmacology Authors: Dominique MazierLaurent RéniaGeorges Snounou Tags: Perspectives Source Type: journals

New medicines to improve control and contribute to the eradication of malariaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
tteridge Despite being one of the most prevalent tropical diseases, for many years malaria was not a commercial priority for the pharmaceutical industry. However, in response to the emergence and spread of resistance to the available antimalarial drugs, there has been a renaissance in the discovery (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 16, 2009 Category: Drugs & Pharmacology Authors: Timothy N. C. WellsPedro L. AlonsoWinston E. Gutteridge Tags: Review Source Type: journals

Stem cells: Tailored drug screeningEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 774 (2009). doi:10.1038/nrd3023 Author: Monica Hoyos Flight Advances in the derivation of induced pluripotent stem cells (iPSCs) from somatic cells have enabled researchers to produce patient-specific cell lines bearing the hallmarks of particular genetic disorders, which can be used to both model the disorder and determine the efficacy of candidate drugs. Writing (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Authors: Monica Hoyos Flight Tags: Research Highlight Source Type: journals

Autoimmune disease: SIRT1 keeps escapees quietEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 772 (2009). doi:10.1038/nrd3022 Author: Gemma Ryan Although self-reactive T cells can escape deletion in the thymus, they are controlled in the periphery by mechanisms that induce tolerance, such as clonal anergy, by which T cells become unresponsive following suboptimal stimulation. The heterodimeric transcription factor activator protein 1 (AP1) is required for (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Authors: Gemma Ryan Tags: Research Highlight Source Type: journals

The evolution of trial registrationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 755 (2009). doi:10.1038/nrd3021 With mandatory clinical trial registration now in place for most novel therapeutic interventions, key questions remain on how to maximize the potential benefits of the enhanced transparency that this provides. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Tags: Editorial Source Type: journals

In this issueEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 753 (2009). doi:10.1038/nrd3020 In response to high-profile drug safety issues in recent years, there has been a growing emphasis on improving the understanding of the safety profile of drugs, both during development and post-approval. Two Perspective articles this month consider the associated challenges and present potential approaches to (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Tags: In This Issue Source Type: journals

Trial watch: Mixed results for novel CD20-targeted antibodyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Trial watch: Mixed results for novel CD20-targeted antibody Nature Reviews Drug Discovery 8, 762 (2009). doi:10.1038/nrd3019 The results of Phase III trials of the CD20-targeted human monoclonal antibody (mAb) ofatumumab in rheumatoid arthritis and non-Hodgkin's lymphoma (NHL) dampen hopes on the potential of the drug to achieve the success of the pioneering CD20-targeted mAb rituximab (Rituxan/MabThera; Genentech/Roche/Biogen Idec).Rituximab, a chimeric (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: journals

News in briefEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 760 (2009). doi:10.1038/nrd3018 NICE responds to report on the value of innovationThe UK's National Institute for Health and Clinical Excellence (NICE) has published its response to the independent report 'Appraising the Value of Innovation'.The lowdown: The report was commissioned by NICE in January 2009 in (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: journals

Patent watchEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 764 (2009). doi:10.1038/nrd3017 Author: Charlotte Harrison Ariad challenges written-description doctrineThe US Court of Appeals for the Federal Circuit (CAFC) has agreed to rehear a case between Ariad and Lilly over Ariad's patent (US 6,410,516) that claims methods of inhibiting the expression of nuclear factor κB (NF-κB) in cells. Earlier this (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Authors: Charlotte Harrison Tags: News and Analysis Source Type: journals

Lessons from the lung for targeted anticancer drugsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 758 (2009). doi:10.1038/nrd3016 Author: Bethan Hughes The growing body of evidence that patients with lung cancer with particular mutations in the gene encoding the epidermal growth factor receptor are more likely to have a better treatment response to gefitinib emphasizes the need for companies to identify the right patients for targeted (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Authors: Bethan Hughes Tags: News and Analysis Source Type: journals

Late-stage osteoporosis drugs illustrate challenges in the fieldEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 757 (2009). doi:10.1038/nrd3015 Author: Alisa Opar FDA committee recommends Amgen's denosumab, for the treatment, but not prevention, of bone loss, while Lilly decides not to submit arzoxifene for regulatory review after 5-year trial. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Authors: Alisa Opar Tags: News and Analysis Source Type: journals

Morgan ShengEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 766 (2009). doi:10.1038/nrd3014 Genentech's Vice President of Neuroscience discusses the company's renewed interest in the area. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: journals

Deal watch : Santhera licenses novel dyskinesia therapy to BiovailEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Deal watch : Santhera licenses novel dyskinesia therapy to Biovail Nature Reviews Drug Discovery 8, 762 (2009). doi:10.1038/nrd3009 Biovail Laboratories has signed an agreement with Santhera Pharmaceuticals, entitling Biovail to the US and Canadian rights to develop and commercialize fipamezole (also known as JP-1730), for the treatment of levodopa-induced dyskinesia in Parkinson's disease. The agreement involves an upfront payment of US$8 million from (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: journals

Drug metabolism: Microbial metabolite predicts human metabolismEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 772 (2009). doi:10.1038/nrd3008 Author: Sarah Crunkhorn Pharmacogenomic analysis is being increasingly investigated for its potential to personalize drug therapy. However, accumulating evidence indicates that factors such as underlying disease, nutrition and gut microbial activity, also have an important role in modulating drug metabolism and response. Now, writing in PNAS, Clayton (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: journals

In BriefEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 774 (2009). doi:10.1038/nrd3007 Cancer (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Tags: Research Highlight Source Type: journals

Neurodegenerative disorders: A biomarker and a target for progressive MSEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 771 (2009). doi:10.1038/nrd3006 Author: Katie Kingwell The course of multiple sclerosis (MS) typically has two phases: relapsing–remitting MS (RRMS), which is characterized by acute autoimmune attacks on the central nervous system (CNS) followed by complete recovery, and secondary progressive MS (SPMS), in which there is progressive and irreversible damage to the (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Authors: Katie Kingwell Tags: Research Highlight Source Type: journals

Fibrotic disease: A pair of novel targetsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 773 (2009). doi:10.1038/nrd3005 Author: Charlotte Harrison Fibrosis — the development of excess connective tissue owing to activation of myofibroblasts — is a key process in the pathophysiology of conditions such as lung injury and kidney disease. Two recent papers in PNAS and Nature Medicine highlight potential new targets for (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Authors: Charlotte Harrison Tags: Research Highlight Source Type: journals

Market watch: Upcoming market catalysts in Q4 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Market watch: Upcoming market catalysts in Q4 2009 Nature Reviews Drug Discovery 8, 763 (2009). doi:10.1038/nrd3004 Author: Ly Jatkoe Key events related to several novel drugs are anticipated in the fourth quarter (Q4) of 2009. One of the most interesting new agents is denosumab (developed by Amgen), a human monoclonal antibody (mAb) that binds to receptor activator of nuclear factor κB ligand (RANKL; also (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Authors: Ly Jatkoe Tags: News and Analysis Source Type: journals

Neuroscience R&DEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Neuroscience R&D Nature Reviews Drug Discovery 8, 825 (2009). doi:10.1038/nrd3001 Central nervous system disorders such as Alzheimer's disease and schizophrenia present substantial unmet treatment needs. Our two interviewees this month discuss their roles in academia and industry helping to translate research in neuroscience into novel therapies for such disorders. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Tags: Careers and Recruitment Source Type: journals

DronedaroneEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
kpatrick In July 2009, dronedarone (Multaq; Sanofi–Aventis), an anti-arrhythmic agent, was approved by the US FDA to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Authors: Richard L. PageBashar HamadPeter Kirkpatrick Tags: News and Analysis Source Type: journals

Psoriasis marketEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 767 (2009). doi:10.1038/nrd2996 Author: Irena Melnikova Psoriasis is a chronic skin disorder characterized by epidermal hyperproliferation and dermal inflammation that vary in severity, from minor, localized patches to complete body coverage. It affects ∼2–3% of the population, making it one of the most prevalent autoimmune diseases worldwide, and can be associated (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Authors: Irena Melnikova Tags: News and Analysis Source Type: journals

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
.-Y. Lee Neuronal inclusions comprised of the microtubule-associated protein tau are found in numerous neurodegenerative diseases, commonly known as tauopathies. In Alzheimer's disease — the most prevalent tauopathy — misfolded tau is probably a key pathological agent. The recent failure of amyloid-β-targeted therapeutics in Phase III clinical (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Authors: Kurt R. BrundenJohn Q. TrojanowskiVirginia M.-Y. Lee Tags: Review Source Type: journals

Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ammock The cardiovascular effects of epoxyeicosatrienoic acids (EETs) include vasodilation, antimigratory actions on vascular smooth muscle cells and anti-inflammatory actions. These endogenous lipid mediators are broken down into diols by soluble epoxide hydrolase (sEH), and so inhibiting this enzyme would be expected to enhance the beneficial (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Authors: John D. ImigBruce D. Hammock Tags: Review Source Type: journals

Tumour-initiating cells: challenges and opportunities for anticancer drug discoveryEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Peter B. Dirks The hypothesis that cancer is driven by tumour-initiating cells (popularly known as cancer stem cells) has recently attracted a great deal of attention, owing to the promise of a novel cellular target for the treatment of haematopoietic and solid malignancies. Furthermore, it seems that tumour-initiating (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - October 1, 2009 Category: Drugs & Pharmacology Authors: Bin-Bing S. ZhouHaiying ZhangMarc DamelinKenneth G. GelesJustin C. GrindleyPeter B. Dirks Tags: Review Source Type: journals

News in briefEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 687 (2009). doi:10.1038/nrd2995 Amgen's bone drug recommended by committeeThe FDA's advisory committee for reproductive-health drugs voted in favour of the use of denosumab (Amgen) to treat bone loss in patients with postmenopausal osteoporosis and in patients undergoing hormone ablation for prostate cancer, but not its use in (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - September 24, 2009 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: journals

Rethinking therapeutic cancer vaccinesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 685 (2009). doi:10.1038/nrd2994 With the first therapeutic cancer vaccine to be approved in the United States or European Union eagerly awaited, Dan Jones investigates the challenges of developing such products. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - September 24, 2009 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: journals

Defining innovationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 683 (2009). doi:10.1038/nrd2993 Author: Bethan Hughes The UK government's plan to define criteria by which new medicines could qualify for a pilot 'Innovation Pass' programme highlights recent discussions in Europe on the value of innovation. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - September 24, 2009 Category: Drugs & Pharmacology Authors: Bethan Hughes Tags: News and Analysis Source Type: journals

Tackling trial troublesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 681 (2009). doi:10.1038/nrd2992 It is increasingly recognized that a key barrier to advancing cancer treatment is the time and resources needed for the initiation and completion of clinical trials of anticancer drugs. How might these challenges be addressed? (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - September 24, 2009 Category: Drugs & Pharmacology Tags: Editorial Source Type: journals

In this issueEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nature Reviews Drug Discovery 8, 679 (2009). doi:10.1038/nrd2991 Pre-competitive collaborations between pharmaceutical companies and the public domain are becoming increasingly common in bioinformatics, in part owing to a growing appreciation that a large amount of bioinformatics data alone does not provide a substantial competitive advantage, and that enhanced public data resources could benefit (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - September 24, 2009 Category: Drugs & Pharmacology Tags: In This Issue Source Type: journals